Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:FBRX NASDAQ:FULC NASDAQ:MCRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$2.56-0.8%$2.95$2.41▼$13.99$239.09M1.21.50 million shs758,325 shsFBRXForte Biosciences$18.54+2.1%$22.83$9.10▼$35.80$252.02M2.87251,133 shs217,127 shsFULCFulcrum Therapeutics$3.76-2.3%$5.92$2.83▼$15.74$256.54M2.934.83 million shs3.67 million shsMCRBSeres Therapeutics$6.83-3.2%$7.43$5.31▼$29.98$68.27M0.1386,464 shs48,871 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-1.16%-4.12%-4.83%-11.11%-73.22%FBRXForte Biosciences+2.15%+5.40%-14.13%-31.36%+30.84%FULCFulcrum Therapeutics-2.34%+7.43%-42.77%-45.82%-47.71%MCRBSeres Therapeutics-3.19%+5.65%-13.83%-26.85%-18.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$2.56-0.8%$2.95$2.41▼$13.99$239.09M1.21.50 million shs758,325 shsFBRXForte Biosciences$18.54+2.1%$22.83$9.10▼$35.80$252.02M2.87251,133 shs217,127 shsFULCFulcrum Therapeutics$3.76-2.3%$5.92$2.83▼$15.74$256.54M2.934.83 million shs3.67 million shsMCRBSeres Therapeutics$6.83-3.2%$7.43$5.31▼$29.98$68.27M0.1386,464 shs48,871 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences-1.16%-4.12%-4.83%-11.11%-73.22%FBRXForte Biosciences+2.15%+5.40%-14.13%-31.36%+30.84%FULCFulcrum Therapeutics-2.34%+7.43%-42.77%-45.82%-47.71%MCRBSeres Therapeutics-3.19%+5.65%-13.83%-26.85%-18.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 2.40Hold$21.33733.33% UpsideFBRXForte Biosciences 2.50Moderate Buy$67.00261.38% UpsideFULCFulcrum Therapeutics 1.75Reduce$8.20118.09% UpsideMCRBSeres Therapeutics 2.25Hold$17.00149.08% UpsideCurrent Analyst Ratings BreakdownLatest MCRB, AVXL, FBRX, and FULC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026MCRBSeres Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/23/2026MCRBSeres Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/23/2026MCRBSeres Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/11/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026FULCFulcrum Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight6/2/2026FULCFulcrum Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeUnderperform ➝ Underweight6/2/2026FULCFulcrum Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.006/2/2026FULCFulcrum Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$4.006/2/2026FULCFulcrum Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$3.006/2/2026FULCFulcrum Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/2/2026FULCFulcrum Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$4.00(Data available from 6/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.10 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$4.71 per shareN/AFULCFulcrum Therapeutics$80M3.13N/AN/A$6.45 per share0.58MCRBSeres Therapeutics$790K83.63$1.05 per share6.49$4.89 per share1.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$46.38M-$0.46N/AN/AN/AN/A-38.76%-35.01%6/30/2026 (Estimated)FBRXForte Biosciences-$69.38M-$4.64N/AN/AN/AN/A-106.17%-85.50%8/13/2026 (Estimated)FULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%8/4/2026 (Estimated)MCRBSeres Therapeutics$5.70M-$5.17N/AN/AN/AN/A-130.29%-35.35%8/5/2026 (Estimated)Latest MCRB, AVXL, FBRX, and FULC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/30/2026Q2 2026AVXLAnavex Life Sciences-$0.07-$0.07N/AN/AN/AN/A5/11/2026Q1 2026FBRXForte Biosciences-$1.16-$1.24-$0.08-$1.24N/AN/A5/5/2026Q1 2026MCRBSeres Therapeutics-$1.88-$2.08-$0.20-$2.08$0.36 million$0.36 million4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/A3/31/2026Q4 2025FBRXForte Biosciences-$1.42-$1.45-$0.03-$1.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A20.8720.87FBRXForte BiosciencesN/A2.752.75FULCFulcrum TherapeuticsN/A34.3334.33MCRBSeres TherapeuticsN/A1.651.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%FBRXForte Biosciences77.63%FULCFulcrum Therapeutics89.83%MCRBSeres Therapeutics59.34%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%FBRXForte Biosciences4.40%FULCFulcrum Therapeutics7.30%MCRBSeres Therapeutics5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4092.67 million82.11 millionOptionableFBRXForte Biosciences513.89 million13.28 millionOptionableFULCFulcrum Therapeutics10066.63 million61.77 millionOptionableMCRBSeres Therapeutics3309.68 million9.18 millionOptionableMCRB, AVXL, FBRX, and FULC HeadlinesRecent News About These CompaniesSeres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50 Day Moving Average - Here's WhyJune 16, 2026 | americanbankingnews.comWe're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn RateJune 13, 2026 | finance.yahoo.comSeres Therapeutics Sets 2026 Annual Shareholder Meeting DateJune 9, 2026 | theglobeandmail.comSeres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of ...June 5, 2026 | finance.yahoo.comSeres Therapeutics Secures $25 Million from Nestlé Health Science and Reduces Facility Costs to Enhance Financial PositionJune 5, 2026 | quiverquant.comQSeres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027June 5, 2026 | globenewswire.comSeres Therapeutics Announces Executive Leadership Changes and PromotionsMay 30, 2026 | theglobeandmail.comSeres Therapeutics (MCRB) Gets a Buy from Canaccord GenuityMay 21, 2026 | theglobeandmail.comSeres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comSeres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 5, 2026 | globenewswire.comSeres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for ...May 4, 2026 | finance.yahoo.comSeres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel DiseaseMay 4, 2026 | globenewswire.comSeres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026April 20, 2026 | globenewswire.comSeres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026April 20, 2026 | globenewswire.comSeres Therapeutics to Present at CARB-X Investor DayApril 9, 2026 | globenewswire.comWhy Seres Therapeutics, Inc.’s (MCRB) Stock Is Up 5.41%March 23, 2026 | aaii.comASeres Therapeutics: Q4 Earnings SnapshotMarch 12, 2026 | khou.comKSeres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesMarch 12, 2026 | globenewswire.comSeres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks TranscriptMarch 3, 2026 | seekingalpha.comSeres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business UpdatesMarch 2, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMCRB, AVXL, FBRX, and FULC Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$2.56 -0.02 (-0.78%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$2.76 +0.20 (+7.97%) As of 05:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Forte Biosciences NASDAQ:FBRX$18.54 +0.39 (+2.15%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$22.20 +3.66 (+19.75%) As of 05:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Fulcrum Therapeutics NASDAQ:FULC$3.76 -0.09 (-2.34%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$3.93 +0.17 (+4.60%) As of 05:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Seres Therapeutics NASDAQ:MCRB$6.82 -0.23 (-3.19%) Closing price 06/24/2026 03:59 PM EasternExtended Trading$6.81 -0.02 (-0.22%) As of 06/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why KB Home Could Reward Patient Investors Later Tesla's New NHTSA Probe Lands at the Worst Possible Time Meta's Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time ASML’s Chip Dominance Runs Into New Silicon Boundaries Frozen Assets: How Super Micro Puts AI Heat on Ice The SpaceX Sell-Off May Be More Than a Market Overreaction Why These South Korea-Focused ETFs Have More Than Doubled in 2026 Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
